Ever Supreme has the ability to self-development, and has a number of cell therapy technologies through technology transfers from Sinica Academy, National Chiao Tung University, and China Medical University.  We have a complete layout in the research and development of new drugs on immune cells and stem cells.

Umbilical cord mesenchymal stem cells (UMC01) for treating acute myocardial infarction (AMI) Phase I clinical trial was approved by the FDA in February 2018, and by TFDA in September of the same year for entering clinical trials; a investigation new drug research for treating stroke by stem cells via intravenous injection (IV) was also approved by the FDA for Phase I clinical-go in September 2018, and also the TFDA Phase I clinical-go in March of 2020.

In addition, the dendritic cell vaccine (ADCV01) for the treatment of malignant brain tumors (GBM) has passed the TFDA review, and the Phase II of clinical trials are currently executing in Chang Gung Medical Hospital of Linkou, Taichung Veteran General Hospital, and the China Medical University Hospital.

In addition, research and development of technologies on chimeric antigen receptor immune cells (CAR001), magnetic fucose nanoparticles, and genetically engineered mesenchymal stem cells are undergoing.